Clinical-stage biopharm company TG Therapeutics today announced that it has initiated a phase I/II trial to evaluate the safety, tolerability, and efficacy of TG-1101, the company’s novel third-generation anti-CD20 monoclonal antibody, in combination with lenalidomide (Revlimid®) for patients with relapsed or refractory B-cell lymphoid malignancies who were previously treated with anti-CD20 antibody therapy.
This 30-patient multi-center trial is TG Therapeutics’ second clinical trial of TG-1101 in North America; the company in September began enrollment of its on-going phase I/II trial with single agent TG-1101 in patients with Non-Hodgkin’s Lymphoma (NHL).
TG-1101 has displayed high single agent activity in a phase I/II clinical trial in patients with relapsed Chronic Lymphocytic Leukemia (CLL), and has been granted orphan status in Europe and in the USA for B-cell CLL.
“We are very excited to announce the launch of our second clinical trial this year for TG-1101, now in combination with lenalidomide, targeting patients with advanced B-cell lymphoid malignancies, including CLL,” Michael S. Weiss, executive chairman and interim CEO, stated in the press release.
Weiss noted that it’s a common belief among lymphoma experts that the combination of anti-CD20 therapy with lenalidomide has the potential to significantly impact the treatment model for patients with B-cell malignancies.
“With a demonstrated ability to induce significantly greater ADCC activity over rituximab, TG-1101 is uniquely positioned to take advantage of the NK-cell activating properties exhibited by lenalidomide; providing a strong biological rationale for clinically meaningful synergy in the combination of these two agents,” Weiss concluded.
For more information visit www.tgtherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment